Considerations When Prescribing Opioids: A Claims Manager's Assessment Framework
Understand the clinical, legal, and regulatory considerations for appropriate opioid prescribing in your insurance claims.
Published 4 April 2026
Introduction
Opioid prescribing in insurance claims requires careful navigation of clinical evidence, regulatory requirements, and risk assessment. As a claims manager, you need to understand what considerations should have been made before opioids are prescribed, what documentation you should expect to see, and what red flags indicate prescribing that may have departed from best practice.
This guide walks you through the seven key considerations that responsible opioid prescribing requires. When these considerations are documented in your claimant's file, you can have confidence that their opioid therapy has been thoughtfully managed. When these considerations are absent, that's your signal to escalate for specialist review.
The Seven Key Considerations for Opioid Prescribing
| Consideration | What You Should Expect to See in Your Claim | Documentation Checklist |
|---|---|---|
| 1. Pre-Prescribing Assessment | Documentation of pain assessment, treatment history, comorbidities, substance use history, and explicit justification for opioid choice over non-opioid alternatives. | Medical records showing pain reassessment; evidence that non-opioid options were tried or considered; documented rationale for opioid initiation. |
| 2. Addiction Risk Screening | Formal addiction risk assessment (e.g., OARRS, ORT, or clinical interview) documented before prescribing. Identification of risk factors and planned mitigation strategies. | Risk assessment tool completed or documented clinical assessment; identified risk factors; planned approach to monitoring and dose titration based on risk. |
| 3. Dose Initiation and Limits | Opioid dosing starts at lower end of evidence-based range. Initial doses are individualized for age, renal function, and prior opioid exposure. Maximum doses follow evidence-based guidance (90-120mg morphine equivalent daily for chronic pain without specialist involvement). | Starting dose documented and justified; consideration of patient factors documented; comparison to evidence-based dose limits if escalation planned. |
| 4. Duration and Monitoring Plans | Intended duration of therapy is defined. Planned review dates are documented. For ongoing therapy, regular assessment of continued clinical need, pain levels, function, and signs of opioid-related harm. | Defined duration at initiation; documented review schedule; evidence of periodic reassessment; monitoring of pain levels, function, and adverse effects. |
| 5. Regulatory Compliance (TGA, PBS, SafeScript/RTPM) | Prescriptions follow TGA scheduling requirements (Schedule 8 for most opioids). PBS restrictions are observed where applicable. Real-Time Prescription Monitoring (RTPM) and SafeScript requirements are met. | Prescription issued through appropriate authority channels; documentation of RTPM checks in patient records; compliance with PBS authority requirements if applicable. |
| 6. Concurrent Medications and Drug Interactions | Documentation that benzodiazepines, other CNS depressants, and other medications have been reviewed for interaction risks. If concurrent CNS depressants prescribed, explicit justification documented and warnings provided about overdose risk. | Medication reconciliation documented; identification of risky concurrent medications; documented discussion of overdose risk if CNS depressants must be co-prescribed. |
| 7. Exit Strategy and De-prescribing Plan | Documentation of planned approach when treatment goals are achieved, pain improves, or opioids are no longer clinically justified. For long-term users, gradual de-prescribing plan with dose reduction schedule and support. | Documented endpoint or "target total daily dose" for escalation; planned approach to cessation; if de-prescribing occurs, dose reduction schedule documented with clinical support plan. |
Consideration 1: Pre-Prescribing Assessment
Before opioids are prescribed, responsible prescribers conduct thorough assessment of why opioids are being considered and whether they're truly the right choice.
Pain Assessment and Diagnosis
You should see documented pain assessment including: location, severity (ideally on a standardized scale), character (nociceptive versus neuropathic), and functional impact. The diagnosis should be clearly linked to the pain complaint. For example, if your claimant has acute post-operative pain, the surgical procedure and recovery timeline should be documented. If chronic pain is the indication, the underlying condition and previous treatment attempts should be documented.
Treatment History: Non-Opioid Options
Good prescribers document what non-opioid approaches have been tried. For musculoskeletal pain, you should expect to see documentation of physiotherapy attempts, anti-inflammatory medications (NSAIDs if appropriate), and possibly psychological therapy. If these haven't been attempted, the documentation should explain why not. When they have been attempted and failed, the documentation should describe why they were insufficient and why opioids are now necessary.
Explicit Rationale for Opioid Choice
You should see a clear statement of why opioids are being prescribed for this claimant at this time. For example: "Given persistent severe pain despite physiotherapy and NSAIDs, opioid analgesia is indicated for acute post-operative recovery and functional restoration" is explicit; silent progression to opioids without documented reasoning is red-flag prescribing.
Consideration 2: Addiction Risk Screening
Before opioids are prescribed, responsible prescribers formally assess addiction risk using validated tools or clinical judgment.
Risk Assessment Tools
Formal risk assessment might use standardized tools such as the Opioid Risk Assessment Tool (ORT) or clinical interview documenting risk factors. Risk factors include prior substance use disorders, personal or family history of addiction, psychiatric conditions, younger age, and social instability. Some claimants are low-risk; others require higher monitoring intensity or alternative pain management approaches.
Risk Stratification and Monitoring Intensity
The documented risk assessment should inform the monitoring plan. Low-risk claimants might require periodic check-ins; higher-risk claimants require more frequent contact, clearer dose limits, or integration with addiction medicine specialists. Your claim documentation should show that risk has been assessed and that monitoring intensity is matched to risk level.
Documented Addiction Counselling
For claimants with significant addiction risk factors, you should expect documentation that the prescriber has discussed addiction risk, provided written warnings about opioid dependence, and discussed planned monitoring and dose limits.
Consideration 3: Dose Initiation and Limits
Opioid dosing is where evidence-based prescribing often breaks down. Your assessment should focus on whether dosing follows evidence-based principles.
Starting Doses and Titration Pace
Evidence-based guidelines recommend starting opioids at low doses (typically 5-10mg morphine equivalent daily for oxycodone, for example) and slowly titrating based on pain response and tolerance. If your claimant starts at higher doses, you should see documented justification such as prior opioid tolerance or severe acute pain. If doses escalate rapidly, you should see documented clinical reasoning (reassessment showing inadequate pain control, functional deterioration justifying dose increase).
Evidence-Based Dose Limits for Chronic Pain
For chronic non-cancer pain, evidence-based guidelines recommend careful specialist assessment if opioid doses exceed 90-120mg morphine equivalent daily. This isn't an absolute prohibition on higher doses; rather, it's a threshold above which specialist evaluation is needed to justify continued escalation. If your claimant's dose is above this threshold without documented specialist input, that's a red flag for prescribing that has drifted from evidence-based practice.
Individualised Dosing for Patient Factors
Older age, renal impairment, hepatic impairment, and low body weight all require dose reductions. If your claimant is elderly or has documented renal or hepatic impairment, check whether opioid doses have been adjusted downward. Failure to do so significantly increases overdose risk.
Consideration 4: Duration and Monitoring Plans
How long should your claimant take opioids? What monitoring occurs during treatment? These should be planned and documented.
Defined Duration for Acute Pain
For acute pain (post-operative, acute injury), opioid therapy should have a defined endpoint. You should see documentation of planned duration (e.g., "morphine for acute post-operative pain for 2-4 weeks, then wean off as pain improves") rather than indefinite prescribing. After that endpoint, the claim should show transition to non-opioid management or documented reassessment if opioids continue.
Planned Reviews and Continued Clinical Need Assessment
For any opioid prescription lasting more than a few weeks, you should see documentation of planned review dates and evidence that reviews have occurred. Each renewal or refill should ideally include documented assessment of: pain levels, functional status, whether therapy is achieving goals, and continued clinical need. Don't expect to see approval of repeat prescriptions without recent clinical documentation supporting continued use.
Monitoring for Opioid-Related Harm
Documentation should include periodic assessment for signs of opioid-related harm: oversedation, respiratory depression, constipation, nausea, cognitive effects. More importantly, monitoring should assess for signs of developing addiction: escalation requests, early refills, drug-seeking behavior, or evidence of multiple prescribers.
Pain and Function Tracking
You should expect to see periodic documentation of pain levels and functional status. Is the opioid therapy achieving the therapeutic goal of improved function and quality of life? Or is your claimant on escalating doses with worsening pain and function? The latter pattern warrants reassessment.
Consideration 5: Regulatory Compliance
Australia's opioid prescribing is governed by TGA scheduling, PBS rules, and recent Real-Time Prescription Monitoring (RTPM) requirements.
TGA Scheduling and Prescription Controls
Most opioids are Schedule 8 (S8) controlled drugs, requiring special prescription pads and prescriber registration. These controls exist to prevent inappropriate prescribing. When you review opioid prescriptions in your claim, they should follow these regulatory requirements. If they don't, that's a red flag.
PBS Authority Requirements
Some opioids require PBS authority approval before supply. For example, extended-release opioids for chronic non-cancer pain may require authority justification. If your claim includes PBS-restricted opioids, check that appropriate authority has been obtained.
Real-Time Prescription Monitoring (RTPM) and SafeScript
Australia's RTPM system allows prescribers to check whether a claimant is obtaining opioids from multiple prescribers. Responsible prescribing includes checking RTPM before prescribing opioids. While you may not see explicit documentation in the claim file, you can ask the prescriber whether RTPM checks have been performed. Absent RTPM checks is a red flag for prescribing that hasn't incorporated opioid safety monitoring systems.
Consideration 6: Concurrent Medications and Drug Interactions
Opioids are particularly dangerous when combined with benzodiazepines or other CNS depressants.
Benzodiazepine and CNS Depressant Interactions
The combination of opioids with benzodiazepines significantly increases overdose risk. If your claimant is prescribed both opioids and benzodiazepines, responsible prescribing includes explicit documentation of: why both are necessary, acknowledgment of overdose risk, and planned monitoring. Concurrent opioids and benzodiazepines without explicit documented justification is prescribing that hasn't accounted for serious safety risks.
Medication Reconciliation and Interaction Screening
Good prescribers review all medications before opioid prescribing to identify potential interactions. This includes not just other prescription drugs but also over-the-counter medications and supplements. You should expect to see documentation of medication review.
Patient Counselling on Drug Interactions
Prescribers should counsel claimants about overdose risk, particularly with concurrent CNS depressants, and advise avoidance of alcohol. While you may not see explicit documentation in every case, asking about this counselling is reasonable when opioids are prescribed with other risky medications.
Consideration 7: Exit Strategy and De-prescribing Plan
How will opioid therapy end? This is often the missing link in opioid prescribing.
Defined Endpoint for Acute Pain
For acute post-operative pain or acute injury pain, the documentation should indicate when opioids will be ceased. Once the acute injury phase is over, transition to non-opioid management should be planned and documented.
Target Total Daily Dose for Chronic Pain
For chronic pain, there should be documentation of a "target" dose where escalation will stop and assessment will occur. This might be documented as "target dose 40mg daily; reassess effectiveness and function at this dose; if inadequate, referral to pain specialist for alternative approaches." This prevents indefinite escalation.
Documented De-prescribing Plan for Long-Term Users
For claimants on long-term opioids who meet criteria for de-prescribing (pain improving, function not improving despite opioids, or other clinical indications), responsible prescribing includes documented de-prescribing plan with gradual dose reduction, timeline, and planned clinical support. Abrupt cessation causes withdrawal symptoms; gradual reduction with support is evidence-based practice.
Integrating These Considerations Into Your Claims Assessment
Step 1: Confirm Pre-Prescribing Assessment
Check claim file for documented pain assessment, diagnosis, trial of non-opioid treatments, and explicit rationale for opioid choice.
Step 2: Verify Addiction Risk Screening
Look for documentation of formal risk assessment tool or clinical assessment of addiction risk. Confirm risk level informs monitoring intensity.
Step 3: Assess Dosing
Compare starting dose to evidence-based guidelines. If dose has escalated, confirm each increase is supported by clinical documentation. If dose exceeds morphine equivalent maximums, check for specialist involvement.
Step 4: Review Monitoring Documentation
Confirm intended duration is documented. Check that periodic reassessments of pain, function, and opioid-related harm have occurred.
Step 5: Confirm Regulatory Compliance
Verify prescriptions follow TGA scheduling, PBS requirements where applicable, and RTPM checks have occurred.
Step 6: Assess Drug Interactions
Look for medication review documentation. If opioids are combined with benzodiazepines, confirm explicit justification is documented.
Step 7: Check for Exit Strategy
For acute pain, confirm planned endpoint is documented. For chronic pain, look for target dose or documented de-prescribing plan.
Key Takeaways for Claims Managers
Responsible opioid prescribing requires consideration of seven key factors. When you see evidence in your claim file that all seven have been thoughtfully addressed and documented, you can have confidence in the prescribing. When multiple considerations are absent, that's your signal to escalate for specialist medication review. A pharmacy-led medication management assessment can provide independent professional evaluation of whether opioid prescribing aligns with these evidence-based considerations and current clinical guidelines for your claimant's specific situation.
For more information about specific Australian regulatory requirements, visit the Therapeutic Goods Administration website or consult with your state's WorkSafe or SIRA authorities for scheme-specific guidance.
Uncertain whether opioid prescribing in your claim aligns with evidence-based considerations? IMM's medication reviews provide comprehensive assessment of opioid therapy appropriateness and documentation of these seven key considerations.
Request a Medication Review
